Geron stock falls 12% after halting Phase 3 IMpactMF trial
FROM THE WIRE · FINANCE.YAHOO.COM
Investing.com -- Geron Corporation (NASDAQ:GERN) shares fell 12% Wednesday after the company announced it would discontinue its Phase 3 IMpactMF trial evaluating imetelstat in JAK inhibitor relapsed/refractory myelofibrosis. Still guessing which stocks will beat the market? Our…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishHalting a Phase 3 trial at a small biotech is relevant for the stock and for the sector.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Geron announced it will discontinue the Phase 3 IMpactMF trial of imetelstat.
- 02The independent Data Monitoring Committee judged it unlikely the trial would meet its primary overall survival endpoint.
- 03Shares fell 12% on Wednesday.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets